News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping
Local Bloggers Cheap Tech Eco-Confessions Faceoff Furst Draft Heard on the Street Med City Movie Guy Pulse on Health Political Party

Search PB Blogs

Loading

Categories

313 posts categorized "Downtown Roch. buzz"

September 01, 2015

Celyad, Medisun collaborating on new China deal

Two international firms with deep Mayo Clinic and Rochester ties are joining forces for a new $22.4 million collaboration. 

Belgium-based Celyad, formerly called Cardio3, announced Monday it's entering into a new venture and distribution deal with its partner, Medisun International Limited, for its C-Cure cardiac treatment. C-Cure is based on stem-cell technology called cardiopoiesis licensed from Mayo Clinic.

CelyadBoth Celyad and the Hong Kong-based Medisun continue to collaborate with Mayo Clinic and both are in the process of creating facilities in Rochester.

This new 15-year agreement between Celyad and Medisun guarantees Celyad will "conduct all clinical development and undertake any regulatory steps necessary for market approval in China, Hong-Kong, Taiwan and Macau (collectively 'Greater China')," according to a news release about the venture.

Medisun will fund that push with a minimum of 20 million Euros, or $22.4 million. In addition to the funding cash, Celyad will collect royalties and profit sharing. The royalty rates, based on the total revenues from C-Cure, are expected to range from 10 percent to 30 percent. Profit-sharing amounts will be based on total revenues after royalties are taken out. The profit sharing is expected to range from 20 to 25 percent.

"We are pleased to have this new license agreement in place with our local partner Medisun, which give us full control over clinical developments in these territories, fully funded by our local partner. Pending receipt of necessary approvals, we look forward to giving access to this technology to patients in Greater China," stated Celyad CEO Christian Homsy in the release.

6a00d83451cc8269e201b8d0c98293970c-120wiCelyad is paying rent on the entire fifth floor, or 14,963 square feet, in the city of Rochester's Minnesota Biobusiness Center. The city signed a lease with Celyad earlier this year for it to develop a prototype manufacturing facility in the downtown building. Construction has been underway for months, but is not yet completed. The five-year lease calls for Celyad to pay a rent of $18 per square foot, or $22,444.50 per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

Local officials hope to convince Celyad to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to officials at Rochester Area Economic Development Inc.  Celyad also has plans to build a U.S. headquarters in Boston.

The company recently reported a $17.04 million loss for the first half of 2015. It lost $18.1 million for the whole year in 2014, up from $15.9 million in losses in 2013. Dr. Homsy told Reuters last week the company has enough cash to make it through the end of 2017.

The company did an initial public stock offering in 2014, which yielded about $500,000 worth of shares for Mayo Clinic.

Medisun also is collaborating with Mayo Clinic on a project to bring more patients from China to Rochester for treatment. While Medisun began building a $1 million office in the H3 Plaza building in downtown Rochester earlier this year, it recently put an end to that project.

Mayo Clinic, however, has confirmed it still is working with Medisun. Mayo Clinic spokeswoman Duska Anastasijevic said she didn't believe "the scope and nature of the relationship has been impacted or altered, just the planned location of their offices has changed." 

She added that Mayo staff working with Medisun said the company will be using one of its Rochester homes as "a guest house" and headquarters for the project. Medisun CEO Danny Wong personally owns two houses in Rochester. He bought a house at 2515 Crest Lane SW for $1.4 million as well as one at 615 10th Ave. SW for $1.31 million. It is not known which property will serve as the guest house.

August 28, 2015

New business is sign of the times in Rochester

There are signs of a new business on the way for North Broadway.

Andy Anderson of Austin has a banner up for a new Fastsigns location coming soon at 200 N. Broadway in the Dison's Cleaners Center.

08272015fastsignsWhile the Fastsigns name is very familiar in the Twin Cities, this will be the Carrollton, Texas-based chain's first appearance in southeastern Minnesota.

"They have been looking to expand into Rochester. With Destination Medical Center, they anticipate growth here will be incredible," said Anderson, who is the co-owner and onsite operator. He's partnering with Gene Clement.

The plan is to start the build out of the location in September and hopefully open in the fall or early winter. He expects to start with three on staff, including himself.

That 1,500-square-foot space was last occupied by the women's clothing resale store called Nu On U, which closed in September. For Med City old timers, that's the spot that previously housed Wireless Toyz and Hobbit Travel back before that.

The real estate deal was handled by Al Watts of Wilson Watts Commercial Real Estate and Bucky Beeman of Realty Growth Inc. The center is owned by Tasos Psomas' Skiathos LLC.

Fastsigns is known for offering a wide array of printed products ranging from banners, signs, vehicle wraps down to flyers and business cards. It's main focus is business-to-business, though it can also handle typical consumer projects.

"We do can anything that a business might need," said Anderson. "Our big things are quality and a very quick turnaround time."

 

August 26, 2015

O&B Shoes to stroll to new home this weekend

Downtown Rochester will see a major migration of Mary Janes, moccasins, mukluks and more this weekend as a crew of between 20 to 30 people march a mountain of shoes to a new storefront.

O&B Shoes will hit the sidewalk this weekend as staff, family and friends move more than $61,000 in shoes, boots and sandals less than a block to the store's new downtown home.

08262015newobshoes"It's going to be a total team effort," said owner Don "Sole Man" Hadley. "We're excited about it. It's going to be a new adventure for me, my staff and my customers."

If everything goes as planned, O&B should re-open on Monday or possibly Tuesday.

O&B Shoes, which has been a downtown feature for 82 years, is moving north from its long-time spot on the corner of 100 First Ave. SW to a new space at 19 First Ave. SW. That's the street-level spot in the Kahler Hotel building where Hanny's Men's Wear operated for decades until that store closed last year. Hanny's still has stores in the Kahler subway.

A crew of between 20 to 30 people is slated to walk the boxes and boxes of footwear to move the 6,000-square-foot storefront. The store will be accessible from the subway, as Hanny's was, although that access won't go through Hanny's store under the space, he said.

O&B shoesO&B, which was founded by Leo Olson and Herbert Bergerson in 1933, has been in its present location since 1976. Its previous downtown spot at 217 Broadway Ave. S. was damaged in a fire.

The prominent spot on the Peace Plaza in the heart of downtown has made O&B a well-known landmark and regular stop for returning Mayo Clinic patients.
08202015cloud9spa
No new tenant for the 100 First Ave. SW storefront has been announced by the building's owner, George Psomas, though signage has gone up for Cloud 9 Spa in the adjacent one. O&B operates its O&B Athletic and O&E (Odds & Ends) Bargain Room in that space on First Avenue. 

August 19, 2015

Mayo Clinic officially opens Mayo Medical Labs expansion

About a year after breaking ground on the project, Mayo Clinic officially opened a 60,000-square-foot expansion of its Superior Drive Support Center on Tuesday.

The Superior Drive Support Center, which houses Mayo Medical Laboratories, is located at 3050 Superior Drive NW. The three-story addition built on the south side of the complex. Mayo Clinic is moving its the toxicology, endocrinology and proteomic core labs to the new space from downtown. They expect to be fully moved in by April.

Moving those three labs out of the Hilton Building will open up 24,000-square-feet of space. While this expansion will not bring new jobs, it will mean moving 150 to 170 people out of downtown to join the more than 1,000 Mayo Medical Labs employees at the Superior Drive complex.

"That's essential to allow other Mayo labs to decompress," said Dr. Matt Binnicker, the chair of the Department of Laboratory Medicine and Pathology's Facilities and Space Committee, in 2014. "Having those labs here makes a lot of sense."


Mayo Medical Labs, which generates revenue for Mayo Clinic, performs about 20 million tests for more than 4,000 hospitals annually.

Binnicker explained that while the three labs handle tests for both Mayo Clinic's patients and Mayo Medical Labs clinical customers, about 90 to 95 percent of their work is for MML.

Mayo Clinic moved into the 13-year-old complex in 2004. By 2011, about 800 employees worked at the facility. It originally was built by electronics manufacturer Celestica Inc. in 2001. When that company closed its Rochester operation, the building was left empty.

Mayo Clinic leased the property for eight years, until it paid $18.5 million in August 2012 to buy it. Before that, it was owned by 17 national investors through Triple Net Properties of Santa Ana, Calif., until they defaulted on the mortgage in 2012. The investors bought the property for $36.8 million in 2006.

When the mortgage defaulted, HSBC Bank USA took over the property. HSCB then sold it to Mayo Clinic.

While it originally was under construction, New York City-based W. P. Carey & Co. LLC bought the complex from Celestica, which leased it back. W.P. Carey later sold it for about 70 percent more than the $21.6 million it paid.

July 23, 2015

Quiet period to end for Celyad (former Cardio3) on July 29

Here's an interesting update from a site called Marketbeat.com about the former Cardio3, now trading in U.S. as Celyad. This Belgium firm has deep ties to Mayo Clinic and will soon occupy an entire floor of the Minnesota Biobusiness Center in downtown Rochester.

 Celyad SA’s  quiet period is set to expire on Wednesday, July 29th. Celyad SA had issued 1,460,000 shares in its initial public offering on June 19th, Market Beat reports.

CelyadThe total size of the offering was $100,097,600 based on an initial share price of $68.56. During Celyad SA’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

 

CYAD has been the subject of a number of recent recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Celyad SA in a research note on Tuesday, July 14th. They set an “overweight” rating and a $95.00 price target on the stock. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Celyad SA in a research note on Sunday, June 21st.

Celyad SA remained flat at $60.44 during during mid-day trading trading on Wednesday. 126 shares of the company’s stock traded hands. Celyad SA has a one year low of $47.52 and a one year high of $67.94. The stock’s 50-day moving average is $54.65 and its 200-day moving average is $54.65.

 

July 22, 2015

Holiday Inn: Roch.'s downtown hotel to close at end of August

Don't expect to book a room in Rochester's downtown Holiday Inn after Aug 31, according to the hotel chain's national reservation line.

Holiday-inn-rochester-3336465069-4x3An InterContinental Hotels representative on the reservation line said this week that Rochester employees said the 170-room hotel at 220 Broadway Ave. S will close at the end of August. They told the ICH representative the closing is because of the sale of the hotel.

For several months, word has been leaking out about a deal to sell the downtown hotel to an unnamed buyer who is planning to convert the 46-year-old hotel into a senior living facility.

If the buzz is correct, these talks have been going on for quite a while without reaching closure. Now the employees are saying a closure is on the way.

At least for the hotel, if not the real estate deal. 

July 17, 2015

Downtown tower's construction waiting on financing

Construction on a 23-story downtown Rochester tower has yet to begin because the developer has not finalized financing for the project, according to a city official.

In May, the City of Rochester pledged $6.5 million in assistance to developer Gus Chafoulias to build his long-planned $140 million Broadway at Center tower. Chafoulias, with limited assistance from his son Andrew Chafoulias and Titan Development and Investments, has been working on different versions of this project since 2007.

TowerBroadway at Center will house a 264-room Hilton Hotel, 33 apartment units and space for office, retail and restaurant use. More than $14 million — including the city's $6.5 million assistance to the developer and the remainder of infrastructure costs — is planned to be reported as Destination Medical Center local contributions and credited toward the city's $128 million commitment.

The tower is to be built on South Broadway and East Center Street, just north of Broadway Residence and Suites by BridgeStreet. Since early last year, buildings that previously housed CJ's Midtown Lounge, Ginny's Fine Fabrics and Jakobson Management Co. have sat empty on the site. When the tenants were asked to vacate, Titan officials estimated that the buildings would be demolished during the summer of 2014.

When approving the project, the city agreed to work in conjunction with the developers to build an attached public parking ramp. But city officials said they have to wait on final paperwork from Titan Development before construction can start.

"Chafoulias indicated a while back that they are still reviewing some of their financing options for the project, so they have not provided us with that signed development agreement as of yet. I'm anticipating it should be fairly soon," City Redevelopment Director Terry Spaeth said. "I know they are looking at a couple different financing options."

The development agreement includes a number of provisions about vacating an alley, conveying properties and approving easements.

Spaeth said it's estimated it will take 22 months, from start to finish, to build Broadway at Center. The city's portion of the project is expected to take nine to 12 months to complete. The plan is for the city work to be completed to coincide with the opening of the overall project.

"Once they get going, I suspect things will get moving pretty rapidly," he said. "The first step is to get the development assistance agreement signed."

When asked about the status of the Broadway at Center project, Titan Marketing and Communications Manager Sheila Thoma said there wasn't much to report.

"I do not have a new/significant update. The project is still on course. With a major project like this, there are a lot of moving parts and it takes time to solidify all details," she wrote in response to inquiries about when the CJ's and Ginny's Fine Fabrics buildings would be demolished.

On May 4, the city approved a development assistance agreement with Titan about Broadway at Center. The Rochester Economic Development Authority, a board comprised of the seven Rochester City Council members, approved $6.5 million in tax increment financing and land write-downs. The EDA had put its development assistance agreement on hold until the Destination Medical Center Corp. board of directors named Broadway at Center as a DMC project. That happened on April 30.

Broadway at Center is reminiscent of a previous project called Time Square that Gus Chafoulias proposed for that block 15 years ago. When Mayo Clinic opted not to lease office space in the $200 million project, Chafoulias withdrew it in 2000.

"This is the single biggest disappointment of my career," Chafoulias said after making the announcement. "It never feels good when you fail. It didn't work out, but it's not the end of the world."

After Chafoulias withdrew, Dubai-based investors stepped in and built a 26-story tower, the tallest building in Rochester, on that corner. That tower, now known as Broadway Residence and Suites, stands next door to the proposed Broadway at Center project.

 

July 14, 2015

Piper Jaffrey gives Celyad (former Cardio3) stock positive rating

Here's an interesting item that floated into my email box this a.m. about the former Cardio3, now trading in U.S. as Celyad. This Belgium firm has deep ties to Mayo Clinic and will soon occupy an entire floor of the Minnesota Biobusiness Center in downtown Rochester.

By the way, a rating of "overweight" is a good thing. It means the stock is a better value that other stocks in the same sector.

Here's the item as posted by Piper Jaffray:

Piper Jaffray initiates coverage on Celyad SA with a Overweight rating and a price target of $95.00.

Analyst Edward Tenthoff commented, "Celyad is a leading cell therapy company. CelyadCelyad is conducting the Phase III CHART-1 trial of autologous cell therapy C-CURE in heart failure patients with data likely next summer. The company will initiate the CHART-2 trial this year with data in 2017. Celyad recently in-licensed novel CAR-T technology for cancer currently in a Phase I AML and multiple myeloma study. Celyad is listed on the EuroNext exchange in Brussels and Paris, and just completed a U.S. IPO issuing 1.46 million shares at US$68.56 raising gross proceed of US$101 million. CYAD shares have sold off since the IPO providing an attractive entry point at US$54.71, in our view. We are initiating coverage with an Overweight rating and US$95 price target."

Shares of Celyad SA closed at $54.71 yesterday.

 

 

June 26, 2015

A taste of the East Coast coming to Med City

The flavor of the East Coast is on its way to southwest Rochester.

Joe Phillips is cooking up a new eatery called Jersey Jo's to serve up "authentic Philly Cheesesteaks and more."

FireShot Capture - Order Online - http___jerseyjos.com_order-onlineHe hopes to be able to open Jersey Jo's by mid-July at 187 16th Ave. SW. Cousins Subs is moving out of that 1,600-square-foot spot in the Shoppes on Second commercial center at the end of June. That address will put him just a couple blocks away from Mayo Clinic's St. Marys Hospital and many hotels.

Phillips, a software programmer who will continue that profession remotely from the restaurant, said this new project started very simply.

"I couldn't get a cheesesteak anywhere around here that I liked," he said. So after years of looking, he finally decided to open a place of his own.

Phillips plans to "import" many of the ingredients for the Jersey Jo's signature cheesesteak sandwiches from the East Coast to create as authentic of a flavor as possible.

In addition to Philly cheesesteaks, Jersey Jo's also will serve cold hoagie sandwiches, chicken wings and a trio of specialty burgers. The meat will be sliced on-site, deli-style for each of the made-to-order sandwiches.

While he has long worked in the technology industry, Phillips knows his way around a kitchen from years in restaurants during college.

Phillips' vision for Jersey Jo's is to create a laid-back place like the small mom-and-pop corner shops he remembers from growing up in New Jersey.

"I want to offer a nondiscriminatory place for people to come and feel welcome while they have some good food," he said.

He expects to have about eight people on staff.

 

June 15, 2015

Former Cardio3 launching $99 million IPO in US and worldwide

Celyad, formerly Cardio3 Biosciences, announced the terms for its $99 million stock offering this morning.

The Belgium-based Celyad, which is building a manufacturing facility in downtown Rochester and has close ties with Mayo Clinic, hopes to raise $99 million by offering 1.4 million shares at $70.98 per share.

CelyadWhile Celyad has traded on the European stock markets of NYSE Euronext Brussels and NYSE Euronext Paris for some time, this stock offering would introduce the regenerative medicine firm directly to the U.S. market. It has applied to make the U.S. offering on the Nasdaq stock market under the symbol CYAD.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. It cannot sell or accept offers to buy until the SEC OKs the registration.

This move could benefit Mayo Clinic, which owned 2.69 percent of Celyad as of March 3. Mayo Clinic first acquired equity in Cardio3 in 2007, when it licensed stem-cell research by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. Its cardiopoiesis technology repairs patients' hearts by re-programming their own stem cells to regenerate cardiac tissue.

Earlier this year, the Rochester City Council recently approved a lease for Celyad to take over the entire fifth floor of Rochester's Minnesota BioBusiness Center. Rochester Area Economic Development Inc. and the Minnesota Department of Employment and Economic Development also are involved in the deal.

Celyad is building a prototype manufacturing facility in the 14,963-square-feet of space on the fifth floor of the downtown building. Mayo, which leases the fourth through eighth floors, moved its employees out of the fifth floor earlier this year. The five-year lease calls for it to pay a rent of $18 per square foot, or $22,444.50, per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

DEED is offering Ceylad a $357,000 Minnesota Job Creation Fund award if it invests $1.5 million in Rochester within a year and hires 33 employees within two years. The average wages of the new jobs will be $21.52 per hour.